125 related articles for article (PubMed ID: 37070619)
21. From "hot spots" to "superscan".
Manier SM; van Nostrand D
Clin Nucl Med; 1983 Dec; 8(12):624-5. PubMed ID: 6653021
[No Abstract] [Full Text] [Related]
22. [Two cases of advanced gastric cancer with diffuse carcinomatosis of the bone marrow showing a widespread osteoplastic bone metastasis].
Kato M; Sugano K; Saito E; Natomi H; Takaku F; Yaui H; Tange T; Fukusato T; Machinami R
Gan No Rinsho; 1990 Mar; 36(4):551-6. PubMed ID: 2157082
[TBL] [Abstract][Full Text] [Related]
23. Clinical Pearls: Etiologies of Superscan Appearance on Fluorine-18-Fludeoxyglucose Positron Emission Tomography-Computed Tomography.
Manov JJ; Roth PJ; Kuker R
Indian J Nucl Med; 2017; 32(4):259-265. PubMed ID: 29142340
[TBL] [Abstract][Full Text] [Related]
24.
Lengana T; Lawal IO; Boshomane TG; Popoola GO; Mokoala KMG; Moshokoa E; Maes A; Mokgoro NP; Van de Wiele C; Vorster M; Sathekge MM
Clin Genitourin Cancer; 2018 Oct; 16(5):392-401. PubMed ID: 30120038
[TBL] [Abstract][Full Text] [Related]
25. Absent or faint renal uptake on bone scan. Etiology and significance in metastatic bone disease.
Kim SE; Kim DY; Lee DS; Chung JK; Lee MC; Koh CS
Clin Nucl Med; 1991 Aug; 16(8):545-9. PubMed ID: 1934804
[TBL] [Abstract][Full Text] [Related]
26. Comparison of bone scintigraphy and
Pyka T; Okamoto S; Dahlbender M; Tauber R; Retz M; Heck M; Tamaki N; Schwaiger M; Maurer T; Eiber M
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2114-2121. PubMed ID: 27290607
[TBL] [Abstract][Full Text] [Related]
27. Fluorocholine PET/CT predicts skeletal progression, skeletal event and cancer specific survival in patients with biochemical relapse for prostate cancer.
Zattoni F; Agostini E; Cattaneo F; Maruzzo M; Basso U; Zattoni F; Evangelista L
Clin Imaging; 2017; 43():110-116. PubMed ID: 28278446
[TBL] [Abstract][Full Text] [Related]
28. Unusual Bone Superscan, MIBG Superscan, and 68Ga DOTATATE PET/CT in Metastatic Pheochromocytoma.
Tan TH; Wong TH; Hassan SZ; Lee BN
Clin Nucl Med; 2015 Nov; 40(11):867-8. PubMed ID: 26252329
[TBL] [Abstract][Full Text] [Related]
29. [Radiologic diagnosis of bone metastases recurrence in patients with prostate cancer treated strontium-89].
Barysheva EV; Selivanov SP; Riannel' IuE; Velichko SA; Usynin EA; Usov VIu
Vestn Rentgenol Radiol; 1999; (5):32-6. PubMed ID: 12717923
[TBL] [Abstract][Full Text] [Related]
30. 18F-FDG PET/CT superscan in prostate cancer.
Bailly M; Besse H; Kerdraon R; Metrard G; Gauvain S
Clin Nucl Med; 2014 Oct; 39(10):912-4. PubMed ID: 24566401
[TBL] [Abstract][Full Text] [Related]
31. Prospective multicenter study of bone scintigraphy in consecutive patients with newly diagnosed prostate cancer.
Zacho HD; Barsi T; Mortensen JC; Mogensen MK; Bertelsen H; Josephsen N; Petersen LJ
Clin Nucl Med; 2014 Jan; 39(1):26-31. PubMed ID: 24217537
[TBL] [Abstract][Full Text] [Related]
32. The diagnostic utility of the flare phenomenon on bone scintigraphy in staging prostate cancer.
Cook GJ; Venkitaraman R; Sohaib AS; Lewington VJ; Chua SC; Huddart RA; Parker CC; Dearnaley DD; Horwich A
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):7-13. PubMed ID: 20697891
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of osseous metastasis in bone scintigraphy.
Davila D; Antoniou A; Chaudhry MA
Semin Nucl Med; 2015 Jan; 45(1):3-15. PubMed ID: 25475375
[TBL] [Abstract][Full Text] [Related]
34. Staging of prostatic carcinoma with radionuclide bone scintigraphy and lymphography.
Hayward SJ; McIvor J; Burdge AH; Jewkes RF; Williams G
Br J Radiol; 1987 Jan; 60(709):79-81. PubMed ID: 3814999
[TBL] [Abstract][Full Text] [Related]
35. Quantitative bone scintigraphy. A methodological evaluation in prostate cancer.
Rydh A; Ahlström KR; Larsson A; Johansson L; Damber JE; Tomiç R; Hietala SO
Acta Radiol; 2000 Mar; 41(2):183-8. PubMed ID: 10741795
[TBL] [Abstract][Full Text] [Related]
36. [Predictive value of prostate-specific antigen and Gleason sum for results of radionuclide bone scintigraphy in patients with prostate cancer].
Wang TY; Chen XP; Li XS; Jia Yx; Cheng J; Zhang JH; Cai L; Zhang Z; Gong K; He ZS; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Aug; 44(4):528-34. PubMed ID: 22898839
[TBL] [Abstract][Full Text] [Related]
37. Detection of the Prostate Cancer Bone Metastases: Is It Feasible to Compare 18F-fluorocholine PET/CT, 18F-fluorodeoxyglucose PET/CT and 99mTc-methyl Diphosphonate Bone Scintigraphy?
Pietrzak AK; Czepczynski R; Wierzchoslawska E; Cholewinski W
Urol J; 2018 Sep; 15(5):242-247. PubMed ID: 29681049
[TBL] [Abstract][Full Text] [Related]
38. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I
J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635
[TBL] [Abstract][Full Text] [Related]
39. The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer.
Rudoni M; Antonini G; Favro M; Baroli A; Brambilla M; Cardani G; Ciardi L; Sacchetti GM; Inglese E
Eur J Nucl Med; 1995 Mar; 22(3):207-11. PubMed ID: 7540551
[TBL] [Abstract][Full Text] [Related]
40. Bony expansion in skeletal metastases from carcinoma of the prostate as seen by bone scintigraphy.
Resnik CS; Garver P; Resnick D
South Med J; 1984 Oct; 77(10):1331-5. PubMed ID: 6484659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
